Protocol Code: SCF-LC-PCRB-DCS-001
Type: Investigational Multi-Drug Regimen (FDA-aligned components; requires clinical oversight)
Purpose: Optimize efficacy + safety + circadian coherence
DOSING PHILOSOPHY (SCF PRINCIPLES)
Key Rules:
- Low-to-moderate dosing with synergy (avoid toxicity stacking)
- Temporal separation of high-risk agents (e.g., fibrinolytics vs anticoagulants)
- Circadian alignment with:
- Immune peaks (morning)
- coagulation peaks (early morning)
- mitochondrial repair (night)
CORE SCF-PCR DRUG STACK (REFERENCE PROTOCOL)
2.1 Curative Layer (C)
Drug | Dose Range (Clinical Reference) | Frequency |
Nirmatrelvir/Ritonavir (Paxlovid) | 300 mg/100 mg | BID (5–10 days cycles) |
Apixaban | 2.5–5 mg | BID |
Low-dose fibrinolytic (e.g., Alteplase microdose)* | 5–10 mg infusion (intermittent) | 1–2× weekly (controlled setting) |
- Investigational adaptation (not standard outpatient use)
2.2 Preventative Layer (P)
Drug | Dose | Frequency |
Baricitinib | 2–4 mg | QD |
Aspirin (low-dose) | 75–100 mg | QD |
Atorvastatin | 10–20 mg | QD |
2.3 Restorative Layer (R)
Drug | Dose | Frequency |
Metformin | 500–1000 mg | BID |
Niacin / NAD⁺ precursor | 250–500 mg | BID |
CoQ10 | 100–200 mg | QD |
CHRONOBIOLOGICAL SEQUENCING MODEL
3.1 Circadian Targets
System | Peak Time | Strategy |
Coagulation | Early morning (4–8 AM) | Pre-emptive anticoagulation |
Immune activation | Morning | Anti-inflammatory dosing |
Mitochondrial repair | الليل (night) | Restorative agents |
Neural/vagal tone | Evening | Neuro-regulation support |
DAILY DOSING SCHEDULE (STANDARDIZED TEMPLATE)
4.1 MORNING (06:00–09:00) — “IMMUNE & COAGULATION CONTROL WINDOW”
Goals:
- Suppress cytokine surge
- Prevent morning hypercoagulability
Administer:
- Baricitinib (QD dose)
- Aspirin (75–100 mg)
- Apixaban (first dose)
- Paxlovid (if active cycle)
4.2 MIDDAY (12:00–14:00) — “STABILIZATION WINDOW”
Goals:
- Maintain metabolic + vascular stability
Administer:
- Metformin (first dose)
- Niacin (first dose)
4.3 EVENING (18:00–20:00) — “SECONDARY CONTROL WINDOW”
Goals:
- Maintain anticoagulation coverage
- Continue antiviral pressure
Administer:
- Apixaban (second dose)
- Paxlovid (second dose)
- Metformin (second dose)
4.4 NIGHT (21:00–23:00) — “RESTORATIVE WINDOW”
Goals:
- Maximize mitochondrial + endothelial repair
- Enhance neural recovery
Administer:
- Atorvastatin
- CoQ10
- Niacin (second dose)
WEEKLY / CYCLIC COMPONENTS
5.1 Fibrinolytic Administration (Controlled Setting)
Parameter | Protocol |
Frequency | 1–2× per week |
Timing | Late morning (10:00–12:00) |
Rationale | Avoid peak coagulation window; monitor safely |
5.2 Antiviral Cycling
- 5–10 day cycles
- Reassess viral persistence biomarkers
- Repeat if indicated
SEQUENCING LOGIC (SCF BRAID DYNAMICS)
6.1 Phase-Weighted Strategy
Phase | Dominant Strand | Adjustment |
Week 1–2 | Curative ↑↑ | Strong antiviral + fibrinolysis |
Week 3–6 | Preventative ↑ | Reduce inflammation, stabilize |
Week 6+ | Restorative ↑↑ | Focus on mitochondrial + neural repair |
6.2 Parallel Maintenance
Even when one strand is dominant:
- Other strands remain active at lower intensity
- Prevents relapse + drift re-entry
BIOMARKER-GUIDED TITRATION
7.1 Key Adjustment Markers
Marker | Action |
D-dimer ↑ | Increase anticoagulation / fibrinolysis |
IL-6 ↑ | Increase anti-inflammatory |
NAD⁺ ↓ | Intensify metabolic support |
HRV ↓ | Increase neuro-restorative support |
SAFETY CONTROL LAYER
8.1 Critical Monitoring
Risk | Monitoring |
Bleeding | INR, platelet count |
Liver function | ALT/AST |
Renal function | Creatinine |
Drug interactions | CYP3A4 (Paxlovid) |
8.2 Contraindication Adjustments
- Reduce fibrinolytics if bleeding risk
- Adjust anticoagulants with renal impairment
- Avoid overlapping strong CYP3A4 drugs
ADVANCED CHRONOTHERAPEUTIC LOGIC
9.1 Circadian Synchronization Effects
- Morning anti-inflammatory → reduces cytokine surge
- Early anticoagulation → prevents clot formation peak
- Night metabolic therapy → enhances mitochondrial repair
9.2 Chrono-Optimization Outcome
- Increased drug efficacy
- Reduced side effects
- Enhanced system coherence
FINAL INTEGRATED MODEL
Time → Target → Therapy
Morning → Immune + coagulation → Anti-inflammatory + anticoagulant
Midday → Stability → Metabolic support
Evening → Maintenance → Anticoagulant + antiviral
Night → Repair → Mitochondrial + neural restoration
FINAL STATEMENT
The SCF-PCR chronobiological dosing protocol transforms a multi-drug regimen into a synchronized biological intervention—aligning therapeutic pressure with circadian system vulnerabilities to maximize efficacy and minimize resistance and toxicity.
MASTER REGISTRY INDEX
- SCF-LC-PCRB-DCS-001 — Dosing & Chronobiology Protocol
- SCF-LC-PCRB-DM-001 — Drug Mapping Matrix
- SCF-LC-VAL-FIAI-001 — Validation Framework
- SCF-LC-CEPM-DE-001 — Controlled Pressure Framework
- SCF-LC-THER-002 — Integrated Therapeutic System